SCHEMBL669507

SCHEMBL669507

Cc1ccc(S(=O)(=O)N[C@@H](Cc2ccccc2)C(=O)C(=O)CCl)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 8/20 0.60
TDP1 Q9NUW8 1/20 0.59
MMP2 P08253 9/20 0.59
ADAMTS4 O75173 1/20 0.59
CTSL P07711 1/20 0.56
ALDH1A1 P00352 2/20 0.56
ADAMTS5 Q9UNA0 1/20 0.56
MAPT P10636 1/20 0.56
POLB P06746 1/20 0.56
CA2 P00918 1/20 0.55
CA7 P43166 1/20 0.55
GAA P10253 1/20 0.53
MMP1 P03956 1/20 0.53
MMP3 P08254 1/20 0.53
MMP7 P09237 1/20 0.53
MMP13 P45452 1/20 0.53
NPY5R Q15761 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213327 1.00 MMP9 (0.60) MMP9TDP1MMP2ADAMTS4CTSL
Tpck SCHEMBL927265 0.89 MMP9 (0.61) MMP9TDP1MMP2ADAMTS4CTSL
Tpck SCHEMBL441444 0.89 MMP9 (0.61) MMP9TDP1MMP2ADAMTS4CTSL
SCHEMBL11146335 0.88 GAA (0.51) MMP9TDP1MMP2ADAMTS4CTSL
SCHEMBL4504106 0.88 MMP9 (0.47) MMP9TDP1MMP2ADAMTS4CTSL
SCHEMBL16401520 0.88 MMP9 (0.47) MMP9TDP1MMP2ADAMTS4CTSL
SCHEMBL1523717 0.86 MMP9 (0.69) MMP9TDP1MMP2ADAMTS4CTSL
SCHEMBL433895 0.86 MMP9 (0.69) MMP9TDP1MMP2ADAMTS4CTSL
SCHEMBL628639 0.86 MMP9 (0.64) MMP9TDP1MMP2ADAMTS4CTSL
Chloromethane SCHEMBL7649372 0.86 MMP2 (0.75) MMP9TDP1MMP2ADAMTS4CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109298176-A Myocarditis quality-control product and preparation method thereof, myocarditis detection kit and myocarditis detection device 深圳天深医疗器械有限公司 2019-02-01 CN claimed
US-8512679-B2 Glassy compositions ELWHA LLC (US) 2013-08-20 US claimed
US-20120225011-A1 Glassy compositions Elwha LLC, a limited liability company of the State of Delaware 2012-09-06 US claimed
EP-1708740-B1 PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES RYTEK (FR) 2010-09-29 EP claimed
US-20080286355-A1 Protease Inhibitors For the Treatment of Digestive Pathologies RYTEK (FR) 2008-11-20 US claimed
CN-1909919-A Composition for the treatment of digestive pathologies RYTEK (FR) 2007-02-07 CN claimed
US-5731198-A COMPRISING AN ENZYME INHIBITOR SUPPORTED ON A POROUS MEMBER EMERALD BIOMEDICAL SCIENCES, INC. (US) 1998-03-24 US claimed
US-5385825-A An enzyme inhibitor consisting of blood, ethylenediamine tetraacetic acid and at least one compound from N-tosyl-lysyl chloromethylketone and N-tosyl-phenylalanyl chloromethylketone ; radioimmunoassay detecting a protein or hormone analyte EMERALD BIOMEDICAL SCIENCES, INC. (US) 1995-01-31 US claimed
JP-5097708-A None JP disclosed
EP-4735035-A2 SARS-COV-2 RNA VACCINES AND USES THEREOF Seqirus Inc. (US) 2026-05-06 EP disclosed
EP-4735034-A2 COMBINATION RNA VACCINE Seqirus Inc. (US) 2026-05-06 EP disclosed
EP-4734962-A1 NOVEL FORMULATIONS RIGImmune Inc. (US) 2026-05-06 EP disclosed
EP-3345919-B1 BINDING DOMAINS DIRECTED AGAINST GPCR: G PROTEIN COMPLEXES AND USES DERIVED THEREOF VIB VZW (BE) 2026-04-01 EP disclosed
US-12590288-B2 Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response THE BROAD INSTITUTE, INC. (US) 2026-03-31 US disclosed
US-4652552-A ENZYME INHIBITORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-03-24 US disclosed
US-4644055-A HALOMETHYL KETONE OR METHYL KETONE COVALENTLY LINKED TO PEPTIDE SEQUENCE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-02-17 US disclosed
US-4636492-A ENZYME INHIBITORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-13 US disclosed
EP-0180288-A2 Vaccine for cytomegalovirus INSTITUT MERIEUX (FR) 1986-05-07 EP disclosed
US-4503035-A HUMAN LEUKOCYTE INTERFERON HOFFMANN-LA ROCHE INC. (US) 1985-03-05 US disclosed
US-4289690-A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TO PURIFY INTERFERON HOFFMANN-LA ROCHE INC. (US) 1981-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590288-B2 Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response GPR3, GALR3, NR4A3 MMP9 4588/4885TDP1 4756/4885MMP2 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.